Table 3.
Correlations between pre-treatment plasma fibrinogen status and clinicopathological features in breast cancer
| Fib status | |||
|---|---|---|---|
| Characteristics | Low (n = 744) | High (n = 260) | P value |
| Age (years) | 0.268 | ||
| ≤ 50 | 430 (75.4%) | 140 (24.6%) | |
| > 50 | 314 (72.4%) | 120 (27.6%) | |
| Menopausal status | < 0.001 | ||
| Pre/peri | 563 (77.4%) | 164 (22.6%) | |
| Post | 181 (65.3%) | 96 (34.7%) | |
| Tumour size (cm) | 0.002 | ||
| ≤ 5 | 609 (76.3%) | 189 (23.7%) | |
| > 5 | 135 (65.5%) | 71 (34.5%) | |
| Lymph node involvement | 0.943 | ||
| No | 270 (74.0%) | 95 (26.0%) | |
| Yes | 474 (74.2%) | 165 (25.8%) | |
| Histological subtype | 0.472 | ||
| IDC | 717 (73.9%) | 253 (26.1%) | |
| Non-IDC | 27 (79.4%) | 7 (20.6%) | |
| HR status | 0.002 | ||
| Positive | 475 (77.5%) | 138 (22.5%) | |
| Negative | 269 (68.8%) | 122 (31.2%) | |
| HER2 statusa | 0.275 | ||
| Positive | 321 (75.2%) | 106 (24.8%) | |
| Negative | 376 (72.0%) | 146 (28.0%) | |
| Ki67 index (%) | 0.052 | ||
| ≤ 14 | 209 (78.6%) | 57 (21.4%) | |
| > 14 | 535 (72.5%) | 203 (27.5%) | |
| Clinical responder | 0.053 | ||
| CR (pCR + cCR) | 162 (81.8%) | 36 (18.2%) | |
| PR | 349 (72.1%) | 135 (27.9%) | |
| SD | 218 (72.4%) | 83 (27.6%) | |
| PD | 15 (71.4%) | 6 (28.6%) | |
a55 cases with unknown HER2 status
Data are presented as number of cases (%)
Abbreviations: Fib fibrinogen, IDC invasive ductal carcinoma, HR hormone receptor, HER2 human epidermal growth factor receptor 2, CR complete response, pCR pathological complete response, cCR clinical complete response, PR partial response, SD stable disease, PD progressive disease